Contrave: Additional Phase III data

Additional data from a completer analysis of the double-blind, U.S. Phase III COR-II (NB-303) trial showed that 48.2% of patients in the high-dose (32 mg naltrexone SR/360 mg bupropion SR) Contrave gr...